Table 2.
Severity and Phenotypes of COVID-19 and Non-COVID-19 Asthmatic
| Variables | Total n=60 | Asthmatic (COVID-19 +) n=10 (16.7%) | Asthmatic (COVID-19 −) n=50 (83.3%) | P value |
|---|---|---|---|---|
| Asthma severity, No. (%) | ||||
| -Intermittent | 21(35%) | 1(10%) | 20(40%) | 0.083 |
| -Mild | 11(18.3%) | 3(30%) | 8(16%) | 0.371 |
| -Moderate | 12(20%) | 0(0%) | 12(24%) | 0.188 |
| -Severe | 16(26.7%) | 6(60%) | 10(20%) | 0.016* |
| Asthma duration ≥ 5 yrs | 26(43.3%) | 6(60%) | 20(40%) | 0.305 |
| ≥1 hospitalization for asthma exacerbation (last year) | 41(68.3%) | 5(50%) | 36(72%) | 0.263 |
| ER visit last year | 59 (98.3%) | 9(90%) | 49(98%) | 0.308 |
| OCS last year (No.) | 57 (95%) | 9(90%) | 47(94%) | 0.528 |
| Previous intubation or PICU admission | 21(35%) | 5(50%) | 16(32%) | 0.298 |
| Associated atopies for at least one | 45(75%) | 10 (100%) | 36 (72%) | 0.097 |
| -Allergic rhinitis | 35 (58.3) | 8 (80%) | 27 (54%) | 0.171 |
| -Eczema | 40 (66.7%) | 6 (60%) | 33 (66%) | 0.728 |
| -Food allergies | 10 (16.7%) | 2 (20%) | 8 (16%) | 0.668 |
| Preadmission eosinophilic counts (cells/µL), median (IQR) | 420(275–625) | 530(52.5–1100) | 420(312.5–570) | 0.921 |
| Eosinophilic asthma (Blood Eos ≥ 300/µL) | 33 (55%) | 5 (50%) | 28 (56%) | 0.742 |
| Serum IgE (IU/mL), median (IQR) | 398(183–249) | 864(534–6240) | 240(93.5–1486) | 0.081 |
| Admission eosinophils counts (cells/µL), median (IQR) | 25(10–112.5) | 10(0–30) | 30(10–130) | 0.118 |
| Neutrophils (Ref: 1500–8500 cells/µL), median (IQR) | 8120(5287.5–10,957.5) | 4810(1707.5–9500) | 8465(5922.5–11,032.5) | 0.075 |
Note: *P < 0.05 (significant).